stooocks.com

Understand any stock in simple English

Pharming Group N.V.

Netherlands 路 Euronext Amsterdam:聽PHAR.AS 路 Market cap: 路 P/E: 路 P/S:

Pharming makes and sells rare-disease medicines, including a protein-replacement therapy for a genetic immune disorder, and earns money from product sales.

Pharming is a small Dutch drugmaker with a very specific job: it makes medicines for people with rare genetic diseases, mostly ones where the body is missing a protein it needs. Its best-known product is a protein-replacement therapy for hereditary angioedema, a condition that causes sudden, painful swelling in the hands, face, gut, and sometimes the airway. Patients either take it when an attack hits or, for some, use it regularly to try to prevent attacks. That drug has been Pharming's money engine for years.

The business is simple in shape. A patient's doctor prescribes the medicine, and Pharming gets paid for each dose sold, through insurers and health systems in the countries where it sells. Rare-disease drugs can carry high prices because the patient group is tiny and the need is serious. The catch is that there are not many patients, so every new country, new approval, or new use matters a lot. Competition comes from other treatments for the same conditions, including Takeda and CSL in the angioedema space. Pharming is trying to become more than a one-drug company. It bought a portfolio of older medicines and has been developing newer treatments, and it has pushed its main drug into more markets, including the United States. That expansion is the story to watch: the core product is mature, so growth has to come from new geographies, new products, and wider use. Like most small biotech-style firms, its fortunes swing on regulatory decisions and on how quickly doctors adopt its drugs.


The company is based in Leiden, in the Netherlands, which helps explain its close ties to European hospitals and regulators even as it sells globally. It is not a giant. It is a specialist that lives or dies on a handful of products, and its investors are essentially betting that it can turn one strong rare-disease franchise into a broader, steadier business.

Saved answer 路 last researched 17 Nov 2026